The development of advanced chemotherapeutic agents often involves intricate synthetic pathways, where the quality of each intermediate directly influences the success of the final product. NINGBO INNO PHARMCHEM CO.,LTD., a respected pharmaceutical intermediate supplier in China, is a key provider of (3R,4S)-1-t-Boc-3-[(triethylsilyl)oxy]-4-phenyl-2-azetidinone (CAS: 149198-47-0). This compound is a critical component in the multi-step synthesis of Cabazitaxel, a significant drug used in the treatment of metastatic prostate cancer.

The synthesis of Cabazitaxel relies on specific stereochemistry, which is carefully controlled by using precisely engineered intermediates. (3R,4S)-1-t-Boc-3-[(triethylsilyl)oxy]-4-phenyl-2-azetidinone, with its specific chiral centers and protective groups, provides the necessary structural framework. NINGBO INNO PHARMCHEM CO.,LTD. ensures that this intermediate meets a high purity standard, with an assay of ≥98.0%, crucial for ensuring the stereospecificity required for Cabazitaxel's therapeutic activity. The compound's molecular formula is C20H31NO4Si, and its molecular weight is 377.550.

The physical characteristics of this intermediate, such as its appearance as a colorless to light yellow oily liquid, are indicative of its refined nature. The compound's stability, supported by its high boiling point and flash point, makes it practical for large-scale industrial synthesis. For pharmaceutical companies looking to buy (3R,4S)-1-t-Boc-3-[(triethylsilyl)oxy]-4-phenyl-2-azetidinone, sourcing from a reputable manufacturer in China like NINGBO INNO PHARMCHEM CO.,LTD. ensures a reliable supply of this vital precursor.

NINGBO INNO PHARMCHEM CO.,LTD.'s expertise as a pharmaceutical intermediate manufacturer in China is central to the efficient production of life-saving drugs. By providing high-quality intermediates, they enable the advancement of medical treatments, including those for cancer. Their commitment to quality assurance and consistent supply underscores their importance in the global pharmaceutical value chain, facilitating the development of next-generation cancer therapies.